|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao B, Wang Q, Zhang H, Zhu G and Lang J:
Two immune-enhanced molecular subtypes differ in inflammation,
checkpoint signaling and outcome of advanced head and neck squamous
cell carcinoma. Oncoimmunology. 7:e13924272017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cooper JS, Pajak TF, Forastiere AA, Jacobs
J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Postoperative concurrent radiotherapy and chemotherapy for
high-risk squamous-cell carcinoma of the head and neck. N Engl J
Med. 350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cooper JS, Zhang Q, Pajak TF, Forastiere
AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Long-term follow-up of the RTOG 9501/intergroup phase III
trial: Postoperative concurrent radiation therapy and chemotherapy
in high-risk squamous cell carcinoma of the head and neck. Int J
Radiat Oncol Biol Phys. 84:1198–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janot F, de Raucourt D, Benhamou E, Ferron
C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing
M, et al: Randomized trial of postoperative reirradiation combined
with chemotherapy after salvage surgery compared with salvage
surgery alone in head and neck carcinoma. J Clin Oncol.
26:5518–5523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolff HA, Overbeck T, Roedel RM, Hermann
RM, Herrmann MK, Kertesz T, Vorwerk H, Hille A, Matthias C, Hess CF
and Christiansen H: Toxicity of daily low dose cisplatin in
radiochemotherapy for locally advanced head and neck cancer. J
Cancer Res Clin Oncol. 135:961–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung CH, Parker JS, Karaca G, Wu J,
Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X,
et al: Molecular classification of head and neck squamous cell
carcinomas using patterns of gene expression. Cancer Cell.
5:489–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walter V, Yin X, Wilkerson MD, Cabanski
CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, et
al: Molecular subtypes in head and neck cancer exhibit distinct
patterns of chromosomal gain and loss of canonical cancer genes.
PLoS One. 8:e568232013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wichmann G, Rosolowski M, Krohn K, Kreuz
M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U,
et al: The role of HPV RNA transcription, immune response-related
gene expression and disruptive TP53 mutations in diagnostic and
prognostic profiling of head and neck cancer. Int J Cancer.
137:2846–2857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Linge A, Lock S, Gudziol V, Nowak A,
Lohaus F, von Neubeck C, Jütz M, Abdollahi A, Debus J, Tinhofer I,
et al: Low Cancer Stem Cell Marker Expression and Low Hypoxia
Identify Good Prognosis Subgroups in HPV(−) HNSCC after
Postoperative Radiochemotherapy: A Multicenter Study of the
DKTK-ROG. Clin Cancer Res. 22:2639–2649. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bernier J, Cooper JS, Pajak TF, van
Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem
J, Ang KK and Lefèbvre JL: Defining risk levels in locally advanced
head and neck cancers: A comparative analysis of concurrent
postoperative radiation plus chemotherapy trials of the EORTC
(#22931) and RTOG (# 9501). Head Neck. 27:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin DC, Xu L, Ding LW, Sharma A, Liu LZ,
Yang H, Tan P, Vadgama J, Karlan BY, Lester J, et al: Genomic and
functional characterizations of phosphodiesterase subtype 4D in
human cancers. Proc Natl Acad Sci USA. 110:6109–6114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Böttcher R, Dulla K, van Strijp D, Dits N,
Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G and
Hoffmann R: Human PDE4D isoform composition is deregulated in
primary prostate cancer and indicative for disease progression and
development of distant metastases. Oncotarget. 7:70669–70684. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Powers GL, Hammer KD, Domenech M,
Frantskevich K, Malinowski RL, Bushman W, Beebe DJ and Marker PC:
Phosphodiesterase 4D inhibitors limit prostate cancer growth
potential. Mol Cancer Res. 13:149–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahrmann EP, Collier LS, Knutson TP, Doyal
ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz
M, et al: Identification of PDE4D as a proliferation promoting
factor in prostate cancer using a Sleeping Beauty transposon-based
somatic mutagenesis screen. Cancer Res. 69:4388–4397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu T, Wu S, Yuan Y, Yan G and Xiao D:
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma
proliferation via the epidermal growth factor receptor signaling
pathway. Oncol Lett. 8:2110–2116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doktorova H, Hrabeta J, Khalil MA and
Eckschlager T: Hypoxia-induced chemoresistance in cancer cells: The
role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc
Czech Repub. 159:166–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Winter SC, Buffa FM, Silva P, Miller C,
Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, et
al: Relation of a hypoxia metagene derived from head and neck
cancer to prognosis of multiple cancers. Cancer Res. 67:3441–3449.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masui T, Ota I, Yook JI, Mikami S, Yane K,
Yamanaka T and Hosoi H: Snail-induced epithelial-mesenchymal
transition promotes cancer stem cell-like phenotype in head and
neck cancer cells. Int J Oncol. 44:693–699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ota I, Masui T, Kurihara M, Yook JI,
Mikami S, Kimura T, Shimada K, Konishi N, Yane K, Yamanaka T and
Kitahara T: Snail-induced EMT promotes cancer stem cell-like
properties in head and neck cancer cells. Oncol Rep. 35:261–266.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu DS, Lan HY, Huang CH, Tai SK, Chang
SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY and Yang MH:
Regulation of excision repair cross-complementation group 1 by
Snail contributes to cisplatin resistance in head and neck cancer.
Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huper G and Marks JR: Isogenic normal
basal and luminal mammary epithelial isolated by a novel method
show a differential response to ionizing radiation. Cancer Res.
67:2990–3001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ricardo S, Vieira AF, Gerhard R, Leitão D,
Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes
J: Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression
distribution within intrinsic molecular subtype. J Clin Pathol.
64:937–946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tabuse M, Ohta S, Ohashi Y, Fukaya R,
Misawa A, Yoshida K, Kawase T, Saya H, Thirant C, Chneiweiss H, et
al: Functional analysis of HOXD9 in human gliomas and glioma cancer
stem cells. Mol Cancer. 10:602011. View Article : Google Scholar : PubMed/NCBI
|
